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Pediatric glaucoma is a potentially blinding disease, account-
ing for about 18% of blindness in blind institutions and 5%
of overall pediatric blindness worldwide (Gilbert et al., 1994;
Gilbert et al., 2003). It has heterogeneous etiologies character-
ized by elevated intraocular pressure (IOP). It is deﬁned as
primary when an isolated, idiopathic developmental anomaly
of the anterior chamber angle exists, and secondary when aque-
ous outﬂow is impaired due to preexisting ocular or systemic
disease (Papadopoulos and Khaw, 2005; Ben-Zion et al.,
2010). In a recent study in the United States, the incidence
of childhood glaucoma was 2.29 per 100,000 (or 1 per
43,575) residents younger than 20 years of age (Aponte
et al., 2010). Acquired (traumatic or surgical, drug-induced
and uveitic) and secondary (e.g. Sturge–Weber syndrome)
forms of glaucoma were the most common, whereas congenital
and juvenile glaucoma were rare (Aponte et al., 2010).
Primary congenital glaucoma (PCG) is the most common
type of glaucoma in infancy (Taylor et al., 1999), and has been
estimated to comprise P5% of the general glaucoma popula
tion of adult Caucasians (Ben-Zion et al., 2011). The incidence
of PCG in Western countries has been estimated at 1 per
10,000 to 1 per 30,200 population (Taylor et al., 1999; Kipp,
2003; deLuise and Anderson, 1983; Miller, 1966; Papadopou-
los et al., 2007; Bermejo and Martinez-Frias, 1998; MacKin-
non et al., 2004). As the disease has an autosomal-recessive
pattern of transmission, it is reported to occur more frequently
in certain ethnic and religious groups where consanguineous
marriage is common (Miller, 1966; Papadopoulos et al.,
2007). The highest reported prevalence has been among indi-
viduals of Slovakian Roma (1 per 1250) (Gencˆı´k, 1989) and
of Saudi Arabian racial descent (1 per 2500) (Jaafar, 1988).2. Management
2.1. Surgical management of pediatric glaucoma
The mainstay of treatment in pediatric glaucoma is the surgical
reduction of intraocular pressure (IOP) (Alsheikheh et al.,2007; Turach et al., 1995), although medical therapy is often
used adjunctively (Maris et al., 2005; Portellos et al., 1998;
Enyedi and Freedman, 2002; Sabri and Levin, 2006). The ulti-
mate goal of IOP reduction is to prevent progressive optic
nerve damage and to maintain visual functioning. However,
even with adequate IOP control, these patients, especially
those with advanced stage of glaucoma, may still have poor vi-
sual function because of prolonged deprivation amblyopia,
corneal opacities, high astigmatism, uncorrected high myopia,
and possible lens subluxation (Ben-Zion et al., 2011; Alshei-
kheh et al., 2007; Robin et al., 1979).
PCG is typically treated with angle surgery ﬁrst. Initial
goniotomy or trabeculotomy have been found to have compa-
rable success rates (deLuise and Anderson, 1983; Meyer et al.,
2000; Yalvac et al., 2007; McPherson and Berry, 1983).
Although goniotomy and trabeculotomy are associated with
good early success rates, eventually 20% of these procedures
fail and many children will require additional surgery to con-
trol the IOP in the long-term (deLuise and Anderson, 1983;
Anderson, 1983; Tanimoto and Brandt, 2006). Furthermore,
some forms of pediatric glaucoma respond poorly to angle sur-
gery and are difﬁcult to treat (deLuise and Anderson, 1983;
Dascotte et al., 1991) Currently, there is no general agreement
as to the preferred surgical algorithm after failure of angle sur-
gery and there is a wide variation in recommended treatment
by centers experienced in the treatment of PCG. Various sur-
gical approaches have been proposed for surgical treatment
of pediatric glaucoma including trabeculectomy with or with-
out adjunctive antimetabolites (Fulcher et al., 1996; Rodrigues
et al., 2004), nonpenetrating deep sclerectomy (Roche et al.,
2007), combined trabeculotomy and trabeculectomy (Mulla-
ney et al., 1999), glaucoma drainage devices (Ben-Zion et al.,
2011; Netland and Walton, 1993; Budenz et al., 2004; van
Overdam et al., 2006; Donahue et al., 1997; Coleman et al.,
1997; Englert et al., 1999; Hamush et al., 1999; Djodeyre
et al., 2001; Hill et al., 2003; Beck et al., 2003; Morad et al.,
2003; Al-Torbak, 2004; Kirwan et al., 2005; Chen et al.,
2005; Kafkala et al., 2005; Pakravan et al., 2007; O’Malley
Schotthoefer et al., 2008; Ou et al., 2009; Al-Mobarak and
Khan, 2009; Yang and Park, 2009), and cyclodestructive pro-
cedures (Al Faran et al., 1990; Phelan and Higginbotham,
Table 1 Studies in which Ahmed glaucoma valve implants were used for the management of pediatric glaucoma.
Studies/Groups No. of eyes (patients;
male: female)
Type of glaucoma Race Mean age ± SD
(range)
Mean follow-up
time ± SD (range)
Mean preoperative
IOP ± SD (mm Hg)
Mean last follow-up
IOP ± SD (mm Hg)
No. of preoperative
medications ± SD
No. of Last
follow-up
medications ± SD
Cumulative probability
of success and Causes of
failure
Coleman et al.
199738
24 (21; 11:10) Congenital = 13
Sturge-Weber
syndrome = 3
Congenital rubella = 2
Traumatic = 2
Osteogenesis
imperfecta = 1
Uveitic = 1
Pesistent hyperplastic
primary surgery = 1
Peter anomaly = 1
Asian = 6
Hispanic = 5
Black = 4
Arab = 3
White = 3
6.61 ± 5.67 years 16.3 ± 11.2 months 30.7 ± 8 (16–46) 19.3 ± 8 1.5 (0–3) 0.8 (0–2.3) 12 months = 77.9%
24 months = 60.6%
Failures = 7
(extrusion of implant = 3;
inadequate IOP control = 3;
suprachoroidal hemorrhage = 1)
Englert et al.
199939
27 (23; 10:13) Congenital = 14
Aphakic = 7
Aniridic = 2
Uveitic = 2
Sturge-Weber
Syndrome = 1
Neovascular = 1
White = 11
Black = 15
American-
Indian = 1
6.44 ± 5.88
(0.3–16.8) years
12.6 ± 8.2 (3–31) months 32.8 ± 7.5 16.4 ± 6.9 2.7 ± 1 0.8 ± 0.7 12 months = 91%
24 months = 58%
Failures = 4 (inadequate IOP control = 2;
retinal detachment = 1; intraocular tumor = 1)
Hamush et al.
199940
11 (10; 5:5) All Sturge-Weber
syndrome
Hispanic = 5
Caucasian = 3
Asian = 1
Arabian = 1
10 days to 25 years 30.35 ± 19.13 months 27.7 4.6 18.5 4.4 1.5 1.4 0.9 0.7 24 months = 79%
48 months = 59%
60 months = 30%
Failure = 4 (implant extrusion = 1;
inadequate IOP control = 3)
Djodeyre et al.
200141
35 (18:17) Congenital = 17
Sturge-Weber
syndrome = 5
Persistence of fetal
vasculature = 4
Congenital cataract = 3
Uveititis in Juvenile
Rheumatoid arthritis = 2
Keratoplasty = 1
Pars planttis = 1
Retinopathy of
prematurity = 1
Stickler syndrome = 1
All white 4.4 ± 4.7 years 12.6 ± 10.8 months 28.8 ± 4.5 (22–40) 18.1 ± 2.4 12 months:
Total = 70.1%
Complete = 67.4%
24 months:
Total = 63.7%
Complete = 44.5%
9 failures =
6 tube malposition
(4 cases tube retracted out of the AC,
1 tube block due to tube-endothelium
contact and 1 tube-iris contact), 3 inadequate
IOP control
Hill et al. 200342 38 (34)
AGV group 18 Congenital = 12
Frank Kamenetsky
Syndrome = 3
Reiger’s Syndrome = 3
Armenians 12.5 ± 2.8 (6–16) years 18.8 ± 9.6 (6–60) months 32 ± 10.1 14.8 ± 5.4 1.9 ± 0.8 0.7 ± 0.8 Total = 16 (88%) Complete = 10 (55%);
Qualiﬁed = 6 (33%); Failure = 2 (12%)
Trab with MMC
group
20 White 12.5 ± 2.4 (10–17) years 16 ± 12.5 (6–60) months 30.1 ± 7.4 13.5 ± 7 2.2 ± 1.1 0.4 ± 0.75 Total = 18 (86%) Complete = 16 (76%);
Qualiﬁed = 2 (10%); failure = 3 (14%)
Beck et al. 200343
AGV group 46 (32) Congenital = 18
Anterior chamber
anomalies = 12
Aphakia = 10
Other = 6
7 5.1 (1–22) months 31.5 ± 22.6 (1–
60) months
32.9 ± 6.5 20.8 ± 8.6 2.4 ± 0.6 1.1 ± 1.1 12 months = 87 ± 10%
72 months = 53 ± 22%
Trab with MMC
group
24 (19) Congenital = 11
Anterior chamber
anomalies = 6
Aphakia = 4
Other = 3
5.3 4.8 (0.5–24) months 11.5 15 (1–60) months 36.4 ± 7.6 27.3 ± 12.2 1.6 ± 0.8 1 ± 1 12 months = 37 ± 16%
72 months = 19 ± 13%
Morad et al. 200344 60 (44; 25:19) Congenital/
infantile = 25/60;
Aphakia = 9/60; Sturge-
Weber synd = 9/60;
Uveitic = 8/60;
Aniridia = 4/60; Anterior
segment dysgenesia = 3/
60; Juvenile = 2/60
6 ± 4.9 years (1.5 months
to 16 years)
24.3 ± 16 (3–60) months 32.8 ± 6.2 (21–50) 16.6 ± 8 (2–57) 4.45 ± 1.97 2 ± 2 12 months = 93%
24 months = 86%
36 months = 71%
48 months = 45%
Al-Torbak 200445 20 (17; 7:10) All congenital 11.7 (2–60) months 30.9 ± 1.1 (18–
60) months
32.3 ± 11.6 19.7 ± 10.6 2.35 ± 0.49 1.6 ± 1.2 2 months = 85%
24 months = 44%
48 months = 33%
Kirwan et al.
200546
19 (13; 7:6) Aphakic 96 (9–189) months 32 (3–84) months 29.7 12.6 100%
(continued on next page)
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Table 1 (continued)
Studies/Groups No. of eyes (patients;
male: female)
Type of glaucoma Race Mean age ± SD
(range)
Mean follow-up
time ± SD (range)
Mean preoperative
IOP ± SD (mm Hg)
Mean last follow-up
IOP ± SD (mm Hg)
No. of preoperative
medications ± SD
No. of Last
follow-up
medications ± SD
Cumulative probability
of success and Causes of
failure
Chen et al. 200547 52 (41; 20:21) Congenital = 20/52;
Aphakic aft. Cong
Cat = 19/52; Sturge-
Weber Syndrome = 5/52;
Aniridia = 4/52;
Uveitic = 2/52; Persistent
hyperplastic primary
vitreous = 2/52
White = 44
African-
American = 3
Asian = 3
Arab = 1
4.9 ± 6.5 (0.02–
18.0) years
2.2 ± 1.8 years
(3 months to7.5 years)
38.1 ± 6.4 21.6 ± 5.9 1 ± 0.8 0.6 ± 0.7 12 months = 85.1%
24 months = 63.2%
36months = 51.7%
48 months = 41.8%
Kafkala et al. 200548 7 (6; 2:4) All uveitis due to:
Juvenile idiopathic
arthritis associated with
iridocyclitis = 4 patients
Sarcoidosis = 1 patient
Pars plantitis = 1 patient
11 (9–13) years 36.8 (6–60) months 37 ± 8 12.1 ± 3.4 3 ± 0.8 0.7 ± 0.7 100%
Pakravan et al. 200749
AGV with MMC group 15 (1512:3) Aphakic 10.9 ± 5.1 (1.5–16) years 13.1 months 31 ± 7.5 14.4 ± 3.5 3.3 ± 0.5 1.6 ± 0.5 Complete = 20%; Qualiﬁed = 66.7%;
Total = 86.7%; Failure: 2
(2 suprachoroidal hemorrhage)
Trabeculectomy with
MMC group
15 (13; 6:7) Aphakic 9.1 ± 4.1 (2–16) years 16.3 months 31 ± 10.7 14.7 ± 4 3 ± 0.6 1.7 ± 0.5 Complete = 33.3; Qualiﬁed = 40%;
Total = 73.3; Failures (1 choroidal
hemorrhage, 1 inadequate IOP control)
O’Malley Schotthoefer et al. 200850
Congenital group 38 (30) 29 14 12 months = 92%
10 years = 42%
Aphakic group 41 (32) 36 15 12 months = 90%
10 years = 55%
Ou et al. 200951 30 (19; 12:7) Primary congenital
glaucoma
White = 8; Asian:
3; Hispanic = 8
1.8 (0.02–9.9) years 57.6 (5–166) months 28.4 ± 6.7(14–40) 17.7 ± 6.7 12 months = 63%
2–3 years = 50%
4 years = 41%
5 years = 33%
Failures = 16 (5 inadequate IOP control;
1 IOP<5 mm Hg; 10 second Ahmed
valve was implanted)
Al-Mobarak and Khan 200952
AGV with MMC group 16 (8:8) Congenital (7/16);
Aphakic (3/16); Peters
anomaly (4/16); Aniridia
(1/16); congenital rubella
(1/16)
10.4 ± 5.3 months 24 months 35.1 ± 11.40 21.3 ± 13.1 2.38 ± 0.70 1.9 ± 1.4 24 months = 31.3%
AGV without MMC group 15 (9:6) Congenital (10/15);
Aphakic (2/15); Peters
anomaly (1/15);Sturge-
Weber syndrome (1/15);
Steroid-induced (1/15)
11.8 ± 5.7 months 24 months 31.6 ± 7.40 18.9 ± 7.2 2.67 ± 0.70 1.13 ± 1.10 24 months: 80%
Yang and Park 200953 34 (29) Congenital = 12
Glaucoma following
lensectomy for congenital
cataracts = 11
Aphakic = 5
Pseudophakic = 6
Aniridia = 1
Microphthalmia = 1
Axenfeld-Rieger
anomaly = 3
Neovascular = 4
Develomental glaucoma
with associated systemic
disease = 1
Glaucoma associated with
cicatrical ROP = 1
5.5 ± 4.2 (0–16) years 29.1 ± 16.2
(6–63) months
37.5 ± 7.3 22.9 ± 11.1 2.3 1.8 6 months = 89%
12 months = 68.6%
24 months = 45.7%
Ben-Zion et al. 20117 AVG = 6 eyes
Trabeculectomy = 31
eyes
PCG Rural Southern
Ethiopia
3.3 (0.4–10) years 6 (1–11) months 54 ± 2 23 ± 2 Those who were implanted with a
shunt device achieved an IOP
<22 mmHg in 75 % of cases.
SD: Standard deviation; AGV: Ahmed glaucoma valve; MMC: Mitomycin C.
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Table 2 Surgical complications following Ahmed glaucoma valve implantation in pediatric glaucoma.
Studies Complications
Coleman et al. (1997) (n= 24 eyes) Scleral graft revision = 4; Extrusion of implant = 3; Tube revision = 3; Pupillary membrane = 2;
Suprachoroidal hemorrhage = 1; Strabismus = 1; Preseptal cellulitis = 1;
Amblyopia/strabismus = 1; Corneal edema = 1
Englert et al. (1999) (n= 27 eyes) Corneal-tube touch = 5; Corneal-tube contact requiring tube revision/trim = 4/27;
Wound leak = 1/27; Vitreous blocking tube = 1/27; Hypotony = 1/27; Shallow AC = 3/27;
Choroidal eﬀusion 2/27; Retinal detachment 1/27; Enucleation for intraocular tumor = 1/27
Hamush et al. (1999) (n= 11) Choroidal detachment = 3 which resolved spontaneouly.
Djodeyre et al. (2001) (n= 35) Tube malposition = 9; Shallow AC = 9; Lens opacity = 6; Choroidal detachment = 6;
Hyphema = 4; Vitreous hemorrhage = 4; Impermeable valve capsule = 3; Ocular hypertension = 3;
Motility limitation = 2; Tube occlusion = 1; Scleral dissolution = 1; Corneal decompensation = 1;
Endophthalmitis = 1; Phthisis bulbi = 1
Hill et al. (2003) (n= 38)
AGV group (n= 18) Tube excursion = 1/18; Reposition of tube = 1/18; Transient shallow AC = 2/18;
Limited choroidal hemorrhage = 2/18; Corneal blood staining = 1/18; Scleral graft thinning = 1/18
Trabeculectomy with MMC group
(n= 20)
Corneal blood staining = 2; Massive choroidal hemorrhage = 1; Choroidal detachment requiring
drainage = 1; Shallow AC requiring reformation = 2; Aqueous misdirection = 1; Lenticular
opaciﬁcation = 6
Beck et al. (2003)
AGV group (n= 46) Tube-cornea touch = 16; Cataract = 5; Corneal decompensation or graft failure = 4;
Shallow AC = 3; Tube/implant exposure = 2; Wound leak = 1; Fibrous in-growth = 1;
Trabeculectomy with MMC group
(n= 24)
Serous choroidal detachments = 4; Shallow AC= 3; Late bleb leak = 3; Late endophthalmitis = 2;
Corneal decompensation = 2; Cataract = 2; Chronic hypotony = 1
Morad et al. (2003) (n= 60) Hypotony (<5 mm Hg) = 14/60; Flat AC = 9/60; Choroidal detachment = 11/60;
Subretinal eﬀusion = 3/60; Exposed tube = 7/60; Tenon’s cyst = 4/60; Endophthalmitis = 3/60;
Retracted tube = 3/60; Wound leak = 2/60; Tub-corneal touch = 2/60;
Iatrogenic Brown Syndrome = 2/60; Vitreous blocking tube = 1/60; Iris blocking tube = 1/60;
Postoperative cataract = 1/60; Late migration into suprachoroidal space = 1/60
Al-Torbak (2004) (n= 20) Subconjunctival scarring = 6; Endophthalmitis = 2; Retinal detachment = 2;
Tube-endothelial-touch = 2; Conjunctival erosion = 1; No light perception = 1;
Conjunctival dehiscence = 1; Tube migrated centrally = 1; Aqueous misdirection = 1;
Phthisis bulbi = 1
Kirwan et al. (2005) (n= 19) Choroidal detachment/hypotony = 2; Corneal touch = 2; Valve removal = 2;
Chen et al. (2005) (n= 52) IOP 65 mm Hg on postoperative day 1 = 22; Shallow AC = 9; Tube occlusion = 7;
Tube-corneal touch = 4; Tube exposure = 3; Tube-associated inﬂammation = 2;
Postoperative cataract = 2; Tenon’s cyst = 2; Hyphema = 1; Pupillary membrane = 1;
Strabismus = 1; Retinal detachment = 1; Endophthalmitis = 1; Choroidal detachment = 1;
None = 8
Kafkala et al. (2005) (n= 7) Hemorrhagic choroidal detachment = 2 (resolved without any surgical intervention)
Pakravan et al. (2007)
AGV with MMC group (n= 15) Choroidal eﬀusion = 2; Suprachoroidal hemorrhage = 2
Trabeculectomy with MMC group
(n= 15)
Choroidal eﬀusion = 4; Vitreous hemorrhage = 1; Endophthalmitis = 1
O’Malley Schotthoefer et al. (2008)
Congenital (n= 38) Pupil abnormalities = 16%; Cataract formation = 20%
Aphakic (n= 41) Pupil abnormalities = 7%
Ou et al. (2009) (n= 30) Tube-cornea touch = 4 eyes (13%); Tube exposure = 2; Transient hypotony (IOP <5 mm Hg) = 2;
Shallow AC requiring reformation = 1; Endophthalmitis = 1; Penetrating Keratoplasty = 3 eyes;
Cataract extraction = 4 eyes; Cycloablative procedure = 3; Enucleation after endophthalmitis
after cataract extraction = 1
Al-Mobarak and Khan (2009)
AGV with MMC group (n= 16) Tube migration requiring intervention = 4; Endophthalmitis = 1; (negative culture);
Preseptal cellulitis = 1
AGV without MMC group (n= 15) Tube migration requiring intervention = 6; Endophthalmitis = 1; (negative culture);
Preseptal cellulitis = 1; Suprachoroidal hemorrhage = 1
Yang and Park (2009) (n= 34) Shallow AC = 3; Hyphema = 2; Hypotony (IOP <5 mm Hg) = 1; Choroidal detachment = 1;
Retinal detachment = 1; Tube exposure: 1; Tube occlusion by iris tissue = 1/34;
No complication = 28/34
Ben-Zion et al. (2011) (n= 6) AGV extrusion = 2
AGV: Ahmed glaucoma valve; MMC: Mitomycin C; AC: Anterior chamber.
Ahmed glaucoma valve in children: A review 3211995; Alvarado, 2007). In this review, we will focus on the
use of Ahmed glaucoma valve (AGV) in pediatric glaucoma
(Table 1).Although success rates of trabeculectomy with mitomycin
C (MMC) were reported in the range of 52–95% (Sidoti
et al., 2000; Beck et al., 1998), in two clinical studies, the suc-
322 N. Nassiri et al.cess rate with AGV was better than that with trabeculectomy
with MMC (Netland and Walton, 1993; Pakravan et al.,
2007). Beck et al. reported a cumulative probability of success
of 87% in the AGV group versus 36% in the trabeculectomy
with MMC group after one year of follow-up. This decreased
to 53% and 19%, respectively, after 6 years of follow-up (Beck
et al., 2003). In a randomized study of eyes with pediatric
aphakic glaucoma, Pakravan et al. (2007) reported success
rates of 87% and 73% after a mean follow-up time of 16.3
and 13.13 months with AGV and trabeculectomy/MMC,
respectively; the IOP reduction and number of glaucoma med-
ications needed were similar in the two groups. Only eyes with
trabeculectomies had postoperative endophthalmitis in both
groups.
2.2. Predictors of surgical failure after AGV implantation in
children
Although different studies have demonstrated considerable
success with AGV in the management of pediatric glaucoma,
it is difﬁcult to compare surgical success rates as these studies
vary widely in the populations studied, study design, deﬁnition
of success and failure, prior glaucoma interventions, type and
severity of glaucoma, and length of follow-up. The reported
success rate ranges from 31% after 24 months in a study by
Al-Mobarak and Khan (2009) and Khan to 86% at 24 months
in a retrospective case series by Morad et al. (2003). The most
common deﬁnition for success has been an IOP 622 mm Hg
with (qualiﬁed) or without (complete) glaucoma medications,
no additional glaucoma surgery, and no visually signiﬁcant
complications (i.e., suprachoroidal hemorrhage, endophthal-
mitis, or retinal detachment). Surgical success has been related
to different factors including longer follow-up time (Table 2)
(Coleman et al., 1997; Englert et al., 1999; Djodeyre et al.,
2001; Beck et al., 2003; Morad et al., 2003; Al-Torbak, 2004;
Chen et al., 2005; O’Malley Schotthoefer et al., 2008; Ou
et al., 2009; Yang and Park, 2009), ethnic background and
gender. Ou et al. (2009) demonstrated a less favorable surgical
outcome in patients of Hispanic ethnicity compared with non-
Hispanic patients (Ou et al., 2009). Female gender and more
advanced glaucoma (with higher IOP and buphthalmos) have
been associated with increased risk of failure (Ben-Zion et al.,
2011; Ou et al., 2009; Al-Mobarak and Khan, 2009).
Some studies indicated that AGV has a higher rate of fail-
ure in patients with PCG compared with patients with other
diagnoses (Coleman et al., 1997; Djodeyre et al., 2001; Chen
et al., 2005). However, other studies have not found any corre-
lation between surgical failure and type of glaucoma (Morad
et al., 2003; O’Malley Schotthoefer et al., 2008; Yang and
Park, 2009) or even reported a higher success rate with PCG
in the pediatric population (Englert et al., 1999). On the other
hand, Chen et al. reported that a diagnosis of aphakic glau-
coma appeared to be associated with a higher success rate
compared to other types of childhood glaucoma (Chen et al.,
2005). Age of the patient has not been found to affect success
rates (Morad et al., 2003; Ou et al., 2009). Morad et al. and
Yang and Park reported that prior glaucoma surgery before
AGV did not affect the success rate (Morad et al., 2003; Yang
and Park, 2009). On the contrary, Djodeyre et al. (2001) noted
that eyes with 2 or fewer previous glaucoma surgeries showed
signiﬁcantly better survival rates. The same investigators ob-
served that more than half of their failures occurred as a resultof tube malposition. Accurate angle of tube entrance into the
anterior chamber, gentle handling of the device, and adequate
ﬁxation are factors related to surgical experience.
There is limited information on whether various types of
drainage devices have different success rates in pediatric glau-
coma. Beck et al. (2003) did not found any statistically signif-
icant difference in IOP control, reduction in the number of
glaucoma medications and success rates between the AGV
(32 eyes) and the Baerveldt implant (14 eyes). On the other
hand, Al-Mobarak and Khan (2009) have shown that silicone
AVIs tend to survive longer than polypropylene AVIs two
years postoperatively. Yang and Park also mentioned that
the success rate may be limited with the AGV model S3, which
has a smaller surface area (96 mm2) (Yang and Park, 2009).
Hence, they proposed that a measurement of globe size with
ultrasound may be useful in deciding the size of the implant
to be used (Yang and Park, 2009).
One of the reasons for failure of glaucoma drainage de-
vices is the development of encapsulated blebs around the
plate. Occasionally, removal of these ﬁbrous capsules leads
to a drop in IOP, but in some patients these cysts reappear
and require repeated surgical procedures (Eibschitz-Tsimhoni
et al., 2005; Feldman et al., 1997; Hill et al., 2000; Trigler
et al., 2006). Surgical removal of the thick capsule around
the plate has been explored shortly (2–6 months) after sur-
gery (Thieme et al., 2011). Histopathologically, the wall of
these encapsulated blebs was found to be very thick (1.5–
2 mm). Macroscopically, the tissue was split into 2 layers.
The smooth inner surface (facing the plate of the AGV) con-
sisted of compressed collagen ﬁbers with signs of elastoid
degeneration along with the formation of a pseudoendotheli-
um toward the plate. There was pronounced transformation
of ﬁbroblasts into myoﬁbroblasts in this inner layer. The out-
er area was highly vascularized. Electron microscopy revealed
thrombosis of these vessels. There was no inﬂammatory re-
sponse in almost all areas of the excised material (Thieme
et al., 2011). Although, in the above study, encapsulation
of bleb did not seem to interfere with the function of the
valve, prior studies have reported on adhesions between the
two membranes forming the valve and ﬁbrovascular tissue in-
growth into the valve mechanism (Feldman et al., 1997; Hill
et al., 2000; Trigler et al., 2006).
There are few data regarding the so-called hypertensive
phase in pediatric population (Nouri-Mahdavi and Caprioli,
2003). The incidence of the hypertensive phase has been re-
ported to be up to 40–59% (Chen et al., 2005; Yang and Park,
2009). Based on the deﬁnition by Nouri-Mahdavi and Caprioli
(2003), Yang and Park (2009) observed resolution of the
hypertensive phase in 75% of their patients, which is much
higher than the reported 28% in adults (Nouri-Mahdavi and
Caprioli, 2003). Chen et al. found that the presence of a hyper-
tensive phase was associated with a signiﬁcantly higher long-
term rate of failure (Chen et al., 2005).
There is also limited information with regard to the efﬁcacy
of intraoperative adjunctive MMC use in pediatric glaucoma
patients. Prior studies of aqueous shunt implantation with
and without adjunctive MMC in adults have not shown a
remarkable beneﬁt to intraoperative MMC use in this setting.
Kirwan et al. (2005) reported that there was no postoperative
difference in IOP measurements or complications in patients
with or without MMC. Al-Mobarak and Khan (2009) demon-
strated that both the cumulative success rate and the mean sur-
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MMC group. However, because of the retrospective nature of
their study, a selection bias based on the type of glaucoma and
prior glaucoma surgeries could not be ruled out. Generally
speaking, adjunctive MMC use for AGV does not seem to im-
prove IOP outcomes and is better avoided, especially since
there is some evidence that it may increase complications
(Minckler et al., 2008, 2006).
2.3. Subsequent surgical procedure after AGV implantation in
children
Surgical treatment of a child with a failed aqueous shunt can
be very challenging. Al-Torbak reported that 45% of eyes
needed subsequent surgery including valve revision in a series
of patients with PCG who underwent combined AVG and
penetrating keratoplasty (Al-Torbak, 2004). Other authors
have reported the need for subsequent surgery in 9–50% of
pediatric patients (Coleman et al., 1997; Djodeyre et al.,
2001; Chen et al., 2005). Additional procedures after pediatric
Ahmed valve surgery may consist of reformation of the ante-
rior chamber, tube-related complications (e.g. extrusion of
the implant), revision of the scleral graft or tube, and periv-
alvular capsulectomy (Coleman et al., 1997; Beck et al., 2003;
Donahue et al., 1997; Chen et al., 2005). Previous studies
showed lower success rates with implantation of a second
glaucoma drainage device compared to the initial shunt
implantation (Burgoyne et al., 2000; Godfrey et al., 2002).
Ou et al. (2009), however, have demonstrated that a second
AGV for further IOP control in children with prior AGV ap-
pears to be safe and effective with a 5-year success rate of
69%. Yang and Park (2009) reported that 46% of their pa-
tients underwent additional AGV without removal of the pri-
mary implant and 80% of these cases survived by the last
follow-up (mean of 26.6 ± 12.7 months). The investigators
considered removal of the primary implant to be traumatic,
and also the possibility that failed valves may still be partially
functioning. Pediatric eyes with previous cyclodestruction
have been noted to have a greater chance of glaucoma con-
trol with aqueous shunt devices than those without previous
cyclodestruction, (Englert et al., 1999) making subsequent
cyclodestruction, either ab interno or ab externo, an option
in the treatment of refractory pediatric glaucoma (Semchy-
shyn et al., 2002). Further studies are required to delineate
the best surgical treatment of pediatric patients who fail an
aqueous shunt procedure.
2.4. Medical treatment after AGV implantation in children
Although the need for glaucoma medications decreases after
placement of a AGV (Coleman et al., 1997; Englert et al.,
1999; Hill et al., 2003; Beck et al., 2003; Morad et al., 2003;
Chen et al., 2005; Pakravan et al., 2007; Ou et al., 2009; Al-
Mobarak and Khan, 2009), most patients will need glaucoma
medications at some point after surgery (Table 2) (Hill et al.,
2003; Pakravan et al., 2007). Ou et al. (2009) reported that
the proportion of eyes requiring medications increased over
5 years of follow-up. While 63% of eyes did not require med-
ications at 3 months, only 11% of the eyes remained off glau-
coma medications at 5 years (Ou et al., 2009). Reduction of the
number of topical glaucoma medications in children is impor-
tant because of the potentially greater systemic side effects thatmay occur due to lack of cooperation in either eyelid closure or
punctual occlusion (Coleman et al., 1997; Zimmerman et al.,
1984).
3. Complications of AGV implantation
Several devastating postoperative complications may occur
following the placement of an AGV in pediatric patients
requiring further surgical management (Table 2). Certain com-
plications from glaucoma drainage implants seem to be more
common in children (Djodeyre et al., 2001; Hill et al., 1991).
Pirouzian and Demer reported that AGV could be associated
with cosmetically signiﬁcant albeit clinically insigniﬁcant
pupillary irregularity, lenticular opaciﬁcation as well as extru-
sion out of anterior chamber, particularly in the ﬁrst year of
life, as the globe is enlarging with age (i.e., buphthalmic pro-
cess) (Pirouzian and Demer, 2008).
3.1. Tube-related complications
Postoperative tube migration (typically anteriorly) is the most
common complication occurring in up to 35% of patients
(Coleman et al., 1997; Englert et al., 1999; Djodeyre et al.,
2001; Beck et al., 2003; Al-Mobarak and Khan, 2009). Tube
migration is thought to be associated with shrinkage of the
sclera and globe after IOP reduction, with the tube reposition-
ing more anteriorly and closer to the corneal endothelium.
Additionally, vigorous eye rubbing can move the tube forward
toward the cornea. Moreover, as the child’s eye grows, the ini-
tially well-positioned tube may rotate more anteriorly over
time. It is recommended that the tube is placed at least 1
mm posterior to the limbus and that the tube is positioned par-
allel to the iris (Englert et al., 1999; Beck et al., 2003; Morad
et al., 2003; O’Malley Schotthoefer et al., 2008).
Tube-cornea touch was reported in as many as 20% of
childhood cases (Mullaney et al., 1999; Englert et al.,
1999; Hill et al., 1991; Fellenbaum et al., 1995). Tube-cornea
contact occurs with higher frequency in buphthalmic pa-
tients (deLuise and Anderson, 1983; Englert et al., 1999).
Yang and Park attributed their low rate of tube-corneal
touch to the application of Ahmed valve S-3 model with
smaller surface area (96 mm2) in patients under 12 years
old (Yang and Park, 2009). A smaller model may be pre-
ferred in pediatric patients to prevent tube-cornea contact,
which tends to occur in the eyes of very young patients with
low scleral rigidity. Transcorneal migration of a tube is an
unusual complication that might result from prolonged
tube-cornea touch (Rosenberg and Krupin, 1996). Reduced
scleral rigidity and especially the long-term memory of the
silicone tube may allow straightening of the tube with time.
Reduced postoperative IOP may lead to shrinkage of the
elastic young eye, shifting the tube anteriorly and causing
cornea touch (Netland and Walton, 1993; Hill et al.,
1991). Local corneal endothelial decompensation from tube
touch has been hypothesized to potentially prompt a toxic
inﬂammatory reaction in thin edematous corneas (Al-Torbak
and Edward, 2001). These events might cause slow corneal
erosion with concurrent scar formation posterior to the
eroding tube, thereby preventing aqueous humor leakage.
Positioning tubes as posteriorly as possible in the anterior
chamber may reduce incidence of tube-cornea touch (Englert
et al., 1999; Djodeyre et al., 2001).
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severe disease with exceptionally high IOP and large horizontal
corneal diameter. Elevated IOP may exert its effect by chang-
ing scleral thickness and rigidity thereby affecting implant sta-
bility (Asejczyk-Widlicka and Pierscionek, 2008). However,
the rigidity of implants (silicone vs. polypropylene) as well as
the difﬁculty in placing scleral sutures in buphthalmic eyes
may have also contributed to the high rate of extrusion (Al-
Mobarak and Khan, 2009). The earlier the AGV placement
is done in life, the higher the probability of tube extrusion (Pir-
ouzian and Demer, 2008). Because it is possible that tube mal-
position and extrusion may result from contraction of the
perivalvular ﬁbrous tissue, placing the tube as posteriorly as
possible in the anterior chamber may reduce the incidence of
this complication (Englert et al., 1999; Djodeyre et al., 2001).
Pirouzian and Demer proposed the tube insertion to be done
through a tangentially curved corneal tunnel in the primary
surgical insertion phase. Once a tube is retracted and/or ex-
truded from anterior chamber, it is able to reinsert the tube
in a straight-line method directly into the chamber in a second-
ary procedure circumventing the requirement for an extender
(Pirouzian and Demer, 2008).
The incidence of tube blockage has been reported to be be-
tween 0% and 14% after AGV in pediatric glaucoma (Rodri-
gues et al., 2004; Roche et al., 2007; Netland and Walton,
1993; Donahue et al., 1997; Hamush et al., 1999). The blockage
may occur due to iris, vitreous, or blood (Sarkisian, 2009). Tube
erosion has been well reported in pediatric glaucoma. Tube
exposure following conjunctival erosion in AGV appeared be
a major risk factor for the development of endophthalmitis
(Al-Torbak et al., 2005). Conjunctival erosion occurs mostly
at the limbus and other locations and it does not appear to
be related to the conjunctival incision line being placed a few
millimeters away from the limbus (Al-Torbak et al., 2005). Rea-
sons for conjunctival erosion over patch grafts and tube are not
totally clear and are possibly multifactorial. Most patients had
multiple previous conjunctival surgeries with exposure to anti-
metabolites and this may contribute to conjunctival erosion
(Al-Torbak et al., 2005). Morad et al. found a signiﬁcant link-
age between uveitis and tube exposure (Morad et al., 2003).
Although the reason is unclear, they explained that the highly
active immune system in these patients overproduces cellular
or humoral factors that eventually cause donor sclera melting
(Morad et al., 2003). However, the high rate of exposure in this
group of patients in their study did not inﬂuence the success
rate in uveitic patients (Morad et al., 2003). The standard of
care to prevent tube erosion is with the use of a patch graft such
as sclera, pericardium, fascia lata, cornea, or amniotic mem-
brane (Sarkisian, 2009).
Careful suturing technique, including securing the tube to
the sclera, can help minimize tube-related complications. This
can prevent many cases of tube and plate migration, retrac-
tion, and erosion. Periodic observation of tube position in
pediatric eyes is highly recommended.
3.2. Ocular hypotony
The reported incidence of hypotony following AGV ranges
from 11% to 25% (Coleman et al., 1997; Englert et al.,
1999; Djodeyre et al., 2001; Morad et al., 2003). However,
Chen et al. reported hypotony in 42% of their patients, which
is comparable to studies involving non-valved implants (Chenet al., 2005). This is higher than that reported in the adult pop-
ulation (<10%) (Sarkisian, 2009). In many of these cases,
anterior chamber reformation or implant revision is required
(Netland and Walton, 1993; Fellenbaum et al., 1995; Nesher
et al., 1992). The management of ﬂat or shallow anterior cham-
bers is more difﬁcult in children, as treatment may often re-
quire repeat general anesthesia.
The possible protective effect of the valve mechanism of the
AGV in reducing postoperative hypotony and shallow anterior
chamber is still unclear. It was suggested that the placement of
the drainage tube through a smaller needle track such as a 23-
(Beck et al., 2003) or 25-(Djodeyre et al., 2001) needle and par-
tially ligating the tube (Chen et al., 2005) might lessen the
chance of leakage around the aqueous drainage implant tube
in patients with extremely thin scleral walls. It is also possible
that a Valsalva maneuver associated with vomiting can cause
hypotony or shallow anterior chamber (Coleman et al.,
1997). Because the tube is placed after anterior or posterior
chamber penetration by a needle, sudden and severe reduction
of the IOP may occur, producing choroidal detachment and
cyclitis, which can lead to hypotony. Unlike non-valved im-
plants, a two-stage procedure is not usually required with
Ahmed valve glaucoma implants. However, if there is height-
ened concern for postoperative hypotony, such as in cases of
Sturge–Weber Syndrome or patients with a history of postop-
erative hypotony in the other eye, a two-stage procedure might
be considered in which the plate is implanted initially and the
tube will be inserted 4–6 weeks later, giving time for the ﬁbrous
capsule to provide resistance to ﬂow. This technique also can
be performed with the Ahmed glaucoma valve (Sarkisian,
2009).
3.3. Motility disturbances
In children, ocular motility disturbances following glaucoma
drainage devices are frequent (Sarkisian, 2009). The incidence
of strabismus after AGV in pediatric patients has been re-
ported in around 3–5% of patients (Coleman et al., 1997; Mor-
ad et al., 2003). The AGV implants seem to produce a lower
incidence of postoperative ocular motility disturbance than
those with larger plate size (Morad et al., 2003). Probably, it
is because of implanting the shunt between rather than par-
tially under the rectus muscles with minimal manipulation of
the muscles (Morad et al., 2003).
The motility problems are believed to be secondary to a
mass effect from the equatorial ﬁltering bleb, a Faden or pos-
terior suture ﬁxation effect, or fat adherence syndrome
(Christmann and Wilson, 1992; Smith et al., 1993; Munoz
and Parrish, 1992). Almost all patients with motility distur-
bance had a large ﬁbrous capsule surrounding the implant
plate, adjacent muscles and sclera (Sarkisian, 2009). Surgical
intervention included muscle surgery, removal of the ﬁbrous
capsule around the implant, and size reduction of the implant
plate (Sarkisian, 2009).
3.4. Infectious endophthalmitis
Infectious endophthalmitis is rare following placement of any
glaucoma drainage devices in children (Hill et al., 1991; Munoz
et al., 1991; Al-Torbaq and Edward, 2002) and is usually de-
layed in onset (Al-Torbak et al., 2005). This devastating com-
plication was reported to be the consequence of conjunctival
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try of the organism (Al-Torbak et al., 2005; Al-Torbaq and Ed-
ward, 2002; Gedde et al., 2001). The rate of endophthalmitis
following AGV surgery in pediatric age group was reported
to be ﬁve times higher than that in adults (Al-Torbak et al.,
2005). Age <18 years old has been reported to be a signiﬁcant
risk factor for endophthalmitis (Al-Torbak et al., 2005). Inter-
estingly, the rate of endophthalmitis in children appears to par-
allel the rate of tube exposure in pediatric shunts (10–13%)
(Djodeyre et al., 2001; Hill et al., 2003; Chen et al., 2005), which
has been reported to be ﬁve times higher than the rate reported
for glaucoma drainage devices in adults (0–2%) (Lloyd et al.,
1994; Melamed et al., 1991). The most frequently detected
organisms causing endophthalmitis following glaucoma drain-
age devices in children areHemophilus inﬂuenzae, Streptococcus
pneumoniae, or both (Al-Torbak et al., 2005). It seems that the
bacillus H. Inﬂuenza is an important source of endophthalmitis
in children because it can be part of the normal bacterial ﬂora
of the conjunctiva and upper respiratory tract, and is a com-
mon cause for infection in both tissues (Al-Torbak et al.,
2005; Al-Torbaq and Edward, 2002; Gedde et al., 2001).
Recommendations for removal of the glaucoma shunt de-
vice at the time of vitrectomy in an eye with endophthalmitis
remain unclear. Although Gedde et al. (2001) and Perkins
(1990) recommended shunt removal at the time of vitrectomy
as shunt might be a reservoir for the infectious organism, oth-
ers have reported successful outcomes with intravitreal antibi-
otics without removal of the shunt device (Al-Torbak et al.,
2005; Al-Torbaq and Edward, 2002; Ellis et al., 1993; Krebs
et al., 1992). In pediatric patients, prompt revision of the ex-
posed valve implants is recommended, as this group of patients
is at a higher risk of endophthalmitis than adults, most likely
due to the higher incidence of upper respiratory tract infections
(Al-Torbak et al., 2005).
3.5. Delayed suprachoroidal hemorrhage
The incidence of delayed suprachoroidal hemorrhage after
glaucoma surgery in children has been reported as 0.36% in
one study (Ghadhfan and Khan, 2009), which is lower than
the reported rate in adults (1.6–6.1%) (Givens and Shields,
1987; Ruderman et al., 1986; Paysse et al., 1996). Aphakia,
AGV implantation, andMMC use were reported as risk factors
for delayed suprachoroidal hemorrhage (Ghadhfan and Khan,
2009). The authors hypothesized that the lack of an intact pos-
terior capsule in pediatric surgical aphakia may decrease the
eye’s ability to tamponade against decompression which makes
delayed suprachoroidal hemorrhage more likely to develop.
Theoretically, AGV implantation should reduce the incidence
of postoperative hypotony and, therefore, would have been ex-
pected to decrease the potential for large rapid changes in the
suprachoroidal vascular gradient and hence delayed supracho-
roidal hemorrhage. Early leakage around the tube or a defec-
tive valve mechanism may have allowed IOPs to reach very
low levels postoperatively (Ghadhfan and Khan, 2009).
3.6. Pupillary irregularities
The mechanism of pupillary peaking toward the tube area is
not well understood. The most likely mechanism of iris peak-
ing might be secondary to inﬂammatory response to the pres-
ence of talc on the tube or local creation of peripheral anteriorsynechia (Pirouzian and Demer, 2008). Occasionally, superﬁ-
cial iris incarceration due to acute decompression during the
creation of the needle track may lead to iris entrapment and
secondary iris elevation. To cope with this adverse outcome,
Pirouzian and Demer suggested manipulating the tube and
inserting the tube in a tangential method posterior to the gray
surgical limbus line to change the direction of the outﬂow (Pir-
ouzian and Demer, 2008). Additionally, they proposed to cre-
ate a surgical peripheral iridectomy, whenever possible at the
entrance site of valve. This may also alter the ﬂuid outﬂow
pathway. Surgical iridectomy may split the ﬂow of aqueous
to the tube oriﬁce into two separate streams emanating from
posterior and/or anterior chambers (Pirouzian and Demer,
2008).
4. Conclusion
The treatment of primary congenital glaucoma and other
childhood glaucomas remains a daunting task, even under
the best of circumstances. The initial learning curve, complica-
tions, longer-term failure, the need for further surgical inter-
ventions have been major obstacles to the management of
pediatric glaucoma. In this review, adequate IOP control can
be achieved with the placement of AGV and can last 5 or more
years. A major challenge is to continue to stimulate interest in
the treatment of pediatric ocular conditions by ophthalmolo-
gists in training. Reduction of visual disability worldwide from
primary congenital glaucoma will only be realized by training
adequate numbers of ophthalmologists, who cannot only diag-
nose the condition, but are willing and able to treat it.References
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